AU2001278705A1 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- AU2001278705A1 AU2001278705A1 AU2001278705A AU7870501A AU2001278705A1 AU 2001278705 A1 AU2001278705 A1 AU 2001278705A1 AU 2001278705 A AU2001278705 A AU 2001278705A AU 7870501 A AU7870501 A AU 7870501A AU 2001278705 A1 AU2001278705 A1 AU 2001278705A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-247948 | 2000-08-10 | ||
JP2000-247947 | 2000-08-10 | ||
JP2000247948 | 2000-08-10 | ||
JP2000247947 | 2000-08-10 | ||
PCT/JP2001/006905 WO2002013816A1 (en) | 2000-08-10 | 2001-08-10 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001278705A1 true AU2001278705A1 (en) | 2002-02-25 |
Family
ID=26598060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001278705A Abandoned AU2001278705A1 (en) | 2000-08-10 | 2001-08-10 | Pharmaceutical composition |
Country Status (5)
Country | Link |
---|---|
US (2) | US6951885B2 (en) |
EP (1) | EP1310248A4 (en) |
AU (1) | AU2001278705A1 (en) |
CA (2) | CA2418224C (en) |
WO (1) | WO2002013816A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY146284A (en) * | 2005-09-14 | 2012-07-31 | Daiichi Sankyo Co Ltd | Substituted cycloalkene derivative |
EP2018855A1 (en) * | 2006-05-15 | 2009-01-28 | Takeda Pharmaceutical Company Limited | Pharmaceutical agent |
GEP20166441B (en) | 2010-01-27 | 2016-03-10 | Takeda Pharmaceutical | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent |
CN109310783B (en) | 2016-03-31 | 2022-06-17 | Mida科技有限公司 | Cyclodextrin-panobinostat adducts |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
JPS6226220A (en) | 1985-07-29 | 1987-02-04 | Hishiyama Seiyaku Kk | Ketoprofen injection |
JPH0796494B2 (en) * | 1988-03-01 | 1995-10-18 | エスエス製薬株式会社 | Oral liquid containing fat-soluble substance |
JPH05139971A (en) | 1991-11-20 | 1993-06-08 | Takada Seiyaku Kk | Isosorbide nitrate injection |
DE69330690T2 (en) * | 1992-01-30 | 2002-06-20 | Takeda Chemical Industries Ltd | Process for the production of highly water-soluble cyclodextrin complexes |
DK0835657T3 (en) | 1992-11-27 | 2005-01-10 | Mayne Pharma Usa Inc | Stable, injectable paclitaxel composition |
JPH06157330A (en) | 1992-11-27 | 1994-06-03 | Ensuiko Sugar Refining Co Ltd | Cyclodextrin clathrate of taxol, it production and use thereof |
JPH08301763A (en) * | 1995-04-28 | 1996-11-19 | Dainippon Pharmaceut Co Ltd | Readily soluble powdery medicinal composition and its production |
AU5780696A (en) | 1995-06-02 | 1996-12-18 | Takeda Chemical Industries Ltd. | Stabilized composition comprising an antiulcerative benzimid azole |
JPH0948730A (en) | 1995-06-02 | 1997-02-18 | Takeda Chem Ind Ltd | Stabilizer composition containing benzimidazole-based anti-ulcer agent having improved water solubility |
US6077871A (en) | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
WO1999046242A1 (en) | 1998-03-09 | 1999-09-16 | Takeda Chemical Industries, Ltd. | Cycloalkene derivatives, process for producing the same, and use |
JP3290970B2 (en) | 1998-07-22 | 2002-06-10 | 山之内製薬株式会社 | Solid preparation containing poorly soluble NSAIDs |
KR20070095416A (en) * | 1999-08-06 | 2007-09-28 | 다케다 야쿠힌 고교 가부시키가이샤 | Substituted aromatic-ring compounds, process for producing the same, and use |
AU776851B2 (en) * | 2000-02-04 | 2004-09-23 | Takeda Pharmaceutical Company Limited | Stable emulsion compositions |
JP2001261557A (en) * | 2000-03-21 | 2001-09-26 | Takeda Chem Ind Ltd | Injection composition having improved dissolution or stability |
-
2001
- 2001-08-10 EP EP01956833A patent/EP1310248A4/en not_active Withdrawn
- 2001-08-10 WO PCT/JP2001/006905 patent/WO2002013816A1/en active Application Filing
- 2001-08-10 CA CA2418224A patent/CA2418224C/en not_active Expired - Lifetime
- 2001-08-10 US US10/343,287 patent/US6951885B2/en not_active Expired - Lifetime
- 2001-08-10 AU AU2001278705A patent/AU2001278705A1/en not_active Abandoned
- 2001-08-10 CA CA2685447A patent/CA2685447C/en not_active Expired - Lifetime
-
2005
- 2005-08-05 US US11/198,710 patent/US7247653B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002013816A1 (en) | 2002-02-21 |
EP1310248A4 (en) | 2008-05-21 |
US20030216475A1 (en) | 2003-11-20 |
CA2418224C (en) | 2010-02-09 |
EP1310248A1 (en) | 2003-05-14 |
US20050272701A1 (en) | 2005-12-08 |
CA2685447C (en) | 2013-05-28 |
US7247653B2 (en) | 2007-07-24 |
US6951885B2 (en) | 2005-10-04 |
CA2418224A1 (en) | 2003-02-03 |
CA2685447A1 (en) | 2002-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU781269C (en) | Pharmaceutical compositions | |
AU2001250420A1 (en) | Pharmaceutical compositions | |
AU2001274307A1 (en) | Pharmaceutical compositions | |
IL152659A0 (en) | Pharmaceutical composition | |
HK1075889A1 (en) | Pharmaceutical composition | |
HUP0204555A3 (en) | Pharmaceutical composition | |
AU2002302147A1 (en) | Pharmaceutical composition | |
AU3556400A (en) | Pharmaceutical compositions | |
AU2002258221A1 (en) | Medicinal composition | |
AU2002214324A1 (en) | Medicinal compositions | |
AU2001290239A1 (en) | Medicinal composition | |
IL154238A0 (en) | Pharmaceutical composition | |
AU2001273919A1 (en) | Pharmaceutical compositions | |
AU6460400A (en) | Pharmaceutical compositions | |
AU4085201A (en) | Pharmaceutical composition | |
AU6460200A (en) | Pharmaceutical compositions | |
AU6460100A (en) | Pharmaceutical compositions | |
AU6460300A (en) | Pharmaceutical compositions | |
AU2001278705A1 (en) | Pharmaceutical composition | |
AU3586401A (en) | Pharmaceutical composition | |
AU2001292578A1 (en) | Pharmaceutical compounds | |
AU2002354460A1 (en) | Medicinal composition | |
AU2001282541A1 (en) | Medicinal compositions | |
AUPR529701A0 (en) | Pharmaceutical composition | |
AU2001285737A1 (en) | Pharmaceutical compositions |